Patient-reported Outcome Claims On Kepivance Site Gets Full Throated FDA Response
This article was originally published in The Pink Sheet Daily
Executive Summary
SOBi’s oral mucositis treatment was studied in controlled trials that used patient-reported outcome measures, but their content validity has not been established, FDA’s Office of Prescription Drug Promotion says.
You may also be interested in...
Mystery Cake Ruins Party For EpiPen TV Ad
Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.
EPO Quality Of Life Claims Unsubstantiated, FDA Says, May Be Cut From Label
FDA is considering deleting patient-reported outcomes claims from epoetin alfa labeling, the agency announced during an advisory committee review of the anemia drug
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.